全文获取类型
收费全文 | 1067870篇 |
免费 | 73106篇 |
国内免费 | 1366篇 |
专业分类
耳鼻咽喉 | 14992篇 |
儿科学 | 34523篇 |
妇产科学 | 28610篇 |
基础医学 | 152386篇 |
口腔科学 | 29531篇 |
临床医学 | 94276篇 |
内科学 | 202581篇 |
皮肤病学 | 24379篇 |
神经病学 | 80868篇 |
特种医学 | 42925篇 |
外国民族医学 | 201篇 |
外科学 | 162528篇 |
综合类 | 21649篇 |
现状与发展 | 1篇 |
一般理论 | 263篇 |
预防医学 | 73994篇 |
眼科学 | 24335篇 |
药学 | 85893篇 |
7篇 | |
中国医学 | 2699篇 |
肿瘤学 | 65701篇 |
出版年
2019年 | 7764篇 |
2018年 | 11309篇 |
2017年 | 8922篇 |
2016年 | 10120篇 |
2015年 | 11286篇 |
2014年 | 15298篇 |
2013年 | 22229篇 |
2012年 | 30601篇 |
2011年 | 32340篇 |
2010年 | 18981篇 |
2009年 | 17841篇 |
2008年 | 29979篇 |
2007年 | 32118篇 |
2006年 | 32739篇 |
2005年 | 31060篇 |
2004年 | 29754篇 |
2003年 | 28513篇 |
2002年 | 27485篇 |
2001年 | 59960篇 |
2000年 | 61376篇 |
1999年 | 50715篇 |
1998年 | 11847篇 |
1997年 | 10390篇 |
1996年 | 10337篇 |
1995年 | 10278篇 |
1994年 | 9317篇 |
1993年 | 8818篇 |
1992年 | 37765篇 |
1991年 | 36270篇 |
1990年 | 35728篇 |
1989年 | 34276篇 |
1988年 | 30848篇 |
1987年 | 29975篇 |
1986年 | 28205篇 |
1985年 | 26441篇 |
1984年 | 19171篇 |
1983年 | 16085篇 |
1982年 | 8792篇 |
1979年 | 16995篇 |
1978年 | 11376篇 |
1977年 | 10193篇 |
1976年 | 8821篇 |
1975年 | 10046篇 |
1974年 | 11633篇 |
1973年 | 11257篇 |
1972年 | 10744篇 |
1971年 | 10084篇 |
1970年 | 9242篇 |
1969年 | 8924篇 |
1968年 | 7907篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
Moreira Daniel C. Venkataraman Sujatha Subramanian Apurva Desisto John Balakrishnan Ilango Prince Eric Pierce Angela Griesinger Andrea Green Adam Eberhardt Charles G. Foreman Nicholas K. Vibhakar Rajeev 《Journal of neuro-oncology》2020,147(3):531-545
Journal of Neuro-Oncology - MYC-driven medulloblastomas are highly aggressive childhood tumors with dismal outcomes and a lack of new treatment paradigms. We identified that targeting replication... 相似文献
43.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
44.
45.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
46.
47.
48.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
49.
50.
Clinical and Translational Oncology - Breast cancer with positive hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) is a special subgroup with different clinical features... 相似文献